Malaria vaccine add-ons activate three antibody targets, study finds

Researchers have discovered that new vaccine formulations can activate three different antibody targets to improve malaria protection. Current WHO-recommended vaccines, RTS,S and R21, help prevent malaria but have limitations in effectiveness and duration. This breakthrough in understanding how vaccine add-ons work could lead to improved malaria vaccines that provide better and longer-lasting protection. With malaria claiming over 500,000 lives annually—primarily young children in Africa—enhancing vaccine effectiveness represents a critical advancement in global public health.

Originally published on
Medical Xpress
Read full article(opens in new tab)Fetched: August 8, 2026 at 10:03 AM



